Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative effectiveness and safety between reduced dose dabigatran, reduced dose rivaroxaban and warfarin in elderly Atrial Fibrillation Patients over 85 years

Trial Profile

Comparative effectiveness and safety between reduced dose dabigatran, reduced dose rivaroxaban and warfarin in elderly Atrial Fibrillation Patients over 85 years

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Jul 2018 Results (n=4722) published in the Journal of the American Geriatrics Society.
    • 28 Nov 2017 New trial record
    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top